About Dr. Liu Xiuhua
Dr. Liu Xiuhua (刘秀华) is a Professor, Doctoral Supervisor, and one of China's leading cardiologists specializing in heart failure and advanced cardiac disease, based at the Department of Cardiology, Changhai Hospital, Naval Medical University (Second Military Medical University). With extensive clinical and research expertise in the diagnosis, management, and device-based treatment of heart failure — including heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and advanced heart failure requiring mechanical circulatory support or cardiac transplantation evaluation — Dr. Liu is recognized as a senior authority in heart failure medicine at one of China's most distinguished military academic medical centers.
Heart failure affects more than 10 million people in China and hundreds of millions worldwide, and its optimal management — combining guideline-directed medical therapy, device-based treatment, and careful monitoring — requires a level of specialist expertise that is available at only a small number of dedicated heart failure centers. The past decade has seen a revolution in heart failure therapy, with the introduction of SGLT2 inhibitors, sacubitril/valsartan (ARNI), and novel device therapies that have dramatically improved outcomes for patients with HFrEF, and growing evidence for targeted therapies in specific heart failure subtypes including cardiac amyloidosis, hypertrophic cardiomyopathy, and HFpEF. Dr. Liu's clinical practice at Changhai Hospital — supported by the hospital's comprehensive cardiac imaging, electrophysiology, and cardiac surgery programs — provides international patients with access to the full spectrum of modern heart failure management, from optimization of guideline-directed medical therapy through device implantation and advanced heart failure evaluation.
Hospital Affiliation: Department of Cardiology, Changhai Hospital
Changhai Hospital (长海医霂), affiliated with Naval Medical University, is one of Shanghai's largest and most prestigious academic medical centers. Its Department of Cardiology is a high-volume, multidisciplinary cardiac program with particular strength in interventional cardiology, electrophysiology, heart failure, and cardiac imaging. The department's heart failure program is supported by a dedicated heart failure clinic with structured follow-up, remote monitoring capabilities, and a multidisciplinary heart failure team integrating cardiology, cardiac surgery, cardiac imaging, cardiac rehabilitation, and palliative care.
The department's device therapy program provides the full range of cardiac implantable electronic devices (CIEDs) for heart failure management: cardiac resynchronization therapy (CRT) and CRT-defibrillator (CRT-D) for HFrEF with left bundle branch block; implantable cardioverter-defibrillators (ICDs) for sudden cardiac death prevention; and evaluation for novel device therapies including cardiac contractility modulation (CCM) and baroreflex activation therapy (BAT) for selected patients. Its advanced heart failure program coordinates evaluation for left ventricular assist device (LVAD) implantation and cardiac transplantation for patients with end-stage heart failure not responsive to optimal medical and device therapy, in collaboration with Changhai Hospital's cardiac surgery department.
Clinical Specialties: What Dr. Liu Xiuhua Treats
- Heart failure with reduced ejection fraction (HFrEF) — optimization of guideline-directed medical therapy (GDMT) including ACE inhibitors/ARBs/ARNI (sacubitril/valsartan), beta-blockers, mineralocorticoid receptor antagonists (MRAs), and SGLT2 inhibitors (dapagliflozin, empagliflozin); titration to target doses; management of HFrEF in the context of ischemic cardiomyopathy, dilated cardiomyopathy, and other etiologies; coordination with interventional cardiology for coronary revascularization in ischemic HFrEF
- Heart failure with preserved ejection fraction (HFpEF) — diagnosis and phenotyping of HFpEF including assessment of filling pressures by echocardiography and invasive hemodynamics; management of HFpEF with SGLT2 inhibitors, diuretics, and treatment of underlying comorbidities (hypertension, atrial fibrillation, obesity, diabetes); evaluation for specific HFpEF etiologies including cardiac amyloidosis, hypertrophic cardiomyopathy, and constrictive pericarditis
- Cardiac amyloidosis — diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) and light chain amyloidosis (AL) cardiac involvement using technetium pyrophosphate (99mTc-PYP) scintigraphy, cardiac MRI, and endomyocardial biopsy; TTR genotyping for hereditary ATTR; tafamidis therapy for ATTR-CM; coordination with hematology for AL amyloidosis treatment; management of heart failure and arrhythmias in cardiac amyloidosis
- Hypertrophic cardiomyopathy (HCM) — diagnosis and risk stratification of HCM including assessment of outflow tract obstruction, diastolic dysfunction, and sudden cardiac death risk; medical management with beta-blockers, verapamil, and disopyramide; mavacamten (cardiac myosin inhibitor) for obstructive HCM; ICD implantation for high-risk patients; coordination with cardiac surgery for septal myectomy and with interventional cardiology for alcohol septal ablation
- Cardiac resynchronization therapy (CRT) and device management — patient selection and implantation coordination for CRT and CRT-D in HFrEF with left bundle branch block; ICD implantation for primary and secondary sudden cardiac death prevention; device optimization and remote monitoring; management of device complications and lead revisions; evaluation for conduction system pacing (His bundle pacing, left bundle branch area pacing) as an alternative to conventional CRT
- Advanced heart failure and mechanical circulatory support — evaluation and management of advanced heart failure (Stage D) not responsive to optimal medical and device therapy; inotropic therapy for acute decompensated heart failure; evaluation for left ventricular assist device (LVAD) implantation as bridge to transplantation or destination therapy; cardiac transplantation evaluation and referral; palliative care integration for end-stage heart failure
- Acute decompensated heart failure — inpatient management of acute decompensated heart failure including diuresis optimization, vasodilator therapy, and inotropic support; management of cardiogenic shock; ultrafiltration for diuretic-resistant fluid overload; transition to outpatient GDMT optimization after stabilization
- Heart failure in specific populations — peripartum cardiomyopathy diagnosis and management; chemotherapy-induced cardiomyopathy and cardio-oncology; heart failure in chronic kidney disease; heart failure management in elderly patients with frailty and polypharmacy
Why International Patients Choose Dr. Liu Xiuhua and Changhai Hospital
International patients seek heart failure consultation with Dr. Liu Xiuhua and Changhai Hospital for reasons that reflect both the clinical depth of her expertise and the comprehensive cardiac infrastructure available at the department.
For patients with HFrEF whose medical therapy has not been optimized to guideline-recommended target doses — a common situation in community cardiology practice worldwide — Dr. Liu's systematic approach to GDMT optimization, including the introduction of SGLT2 inhibitors and sacubitril/valsartan where not yet prescribed, frequently achieves meaningful improvements in ejection fraction and functional capacity that have not been achieved with prior management. The availability of the full range of GDMT agents at Changhai Hospital — including sacubitril/valsartan and SGLT2 inhibitors at costs substantially below those in Western healthcare systems — makes optimal medical therapy accessible to international patients who cannot afford these agents at home.
For patients with HFpEF — a condition for which effective therapies have historically been limited but for which SGLT2 inhibitors now provide meaningful benefit — Dr. Liu's expertise in HFpEF phenotyping and her systematic approach to identifying and treating specific HFpEF etiologies including cardiac amyloidosis and hypertrophic cardiomyopathy provides a level of diagnostic and therapeutic precision that is difficult to access outside specialized heart failure centers.
For patients with cardiac amyloidosis — a condition that is frequently underdiagnosed and for which disease-modifying therapy with tafamidis is now available for ATTR-CM — Dr. Liu's expertise in amyloidosis diagnosis and management provides access to the diagnostic workup and treatment that can slow disease progression and improve outcomes in this previously untreatable condition.
What to Expect at Your Consultation
Consultations with Dr. Liu Xiuhua at Changhai Hospital arranged through CMCS begin with a comprehensive review of all prior cardiac records — including echocardiography reports, cardiac MRI, ECG, Holter monitor results, cardiac catheterization reports, prior device interrogation reports, BNP/NT-proBNP trends, renal function and electrolytes, current medications and prior medication history, and the patient's heart failure symptom history including NYHA functional class, exercise tolerance, and fluid status. CMCS will arrange certified translation of all medical records and investigation results in advance of the consultation.
Dr. Liu will assess the heart failure etiology, severity, and current management, identify opportunities for GDMT optimization and device therapy, evaluate for specific heart failure etiologies requiring targeted treatment, and outline a comprehensive management plan with detailed rationale. A written English-language consultation summary is provided after every appointment, and CMCS will facilitate direct communication between Dr. Liu's team and the patient's home cardiologist for continuity of care planning.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides comprehensive end-to-end support for international patients seeking heart failure consultation with Dr. Liu Xiuhua at Changhai Hospital. Our services include priority consultation scheduling, certified medical record and echocardiography report translation, coordination of cardiac imaging and laboratory investigations, on-site interpretation throughout the consultation, medication coordination and pharmacy support, and written English-language reporting of all findings and recommendations. CMCS will also facilitate direct communication between Dr. Liu's team and the patient's home cardiologist to ensure seamless continuity of care.
📧 contract@medicalsh.com | 💬 WeChat: gezhanglao | 🌐 medicalsh.com
0件のコメント